We developed 2bF9 transgenic mice in a hemophilia B mouse model with the expression of human factor IX (FIX) 
Introduction
Hemophilia B is an X-linked, recessive bleeding disorder that results from a deficiency of blood coagulation factor IX (FIX). Gene therapy is an attractive alternative for hemophilia B treatment because it may provide a continuous level of FIX expressed from the genetically modified cells. Currently, the most common gene therapy strategy for hemophilia B trials attempts to produce FIX with constitutive secretion into plasma to achieve therapeutic effects. Muscle and liver are the two main targets for hemophilia B gene therapy using AAV vector. [1] [2] [3] [4] The development of inhibitory antibodies against the exogenous protein or the viral vector remains a major problem in clinical gene transfer trials. 5 Platelets, which are produced through hematopoiesis by budding off from megakaryocytes, 6 can be a unique target for gene therapy for some diseases due to their special characteristics serving as both storage "depot " and trafficking "vehicle". α-granules are the most numerous storage granules in platelets and many different kinds of protein are stored in α -granules. 7 These proteins are either synthesized in platelets or endocytosed from plasma, and they can be secreted following stimulation. 8;9 Recent evidence indicates that there are different types of α -granules containing different proteins with distinct functions. 10;11 Previous work on factor VIII (FVIII) in hemophilia A mice done by our group and others has demonstrated that targeting FVIII expression to platelets results in storage of FVIII in
For personal use only. on October 24, 2017 . by guest www.bloodjournal.org From α -granules, [12] [13] [14] [15] and that this corrects murine hemophilia A even in the presence of high titers of anti-FVIII inhibitory antibodies. 15;16 Although co-expression with the FVIII carrier protein, von Willebrand factor (VWF), is important for optimal FVIII synthesis and/or storage in platelets, FVIII can still be stored in α-granules even in the absence of VWF. 15;17 These results suggest that α -granules can serve as a storage pool for proteins and can be used as part of a gene therapy strategy. Normally, FIX is synthesized in hepatocytes and is secreted constitutively into the blood circulation. We wanted to explore expression of FIX in platelets to determine if FIX is stored, released, and effective. We hypothesize that expressing FIX in platelets will enable storage of FIX in platelet α -granules and that it will be locally released upon injury, increasing FIX concentration at the local injury site. We developed transgenic mice on a FIX deficient (FIX For personal use only. on October 24, 2017 . by guest www.bloodjournal.org From
Materials and methods

Vector construction
The human FIX cDNA was previously developed by Walsh and co-workers. 18 An XhoI site was introduced at the 5' end of the FIX cDNA by site-directed mutagenesis. FIX cDNA was excised by XhoI and SalI and subcloned into plasmid α IIb-pCIneo generated in our laboratory previously, 14 placing the FIX cDNA under control of the α IIb promoter (2bF9). The 2bF9 expression cassette was then excised by I-PpoI and SalI and cloned into lentiviral vector pWPT-2bF8 in place of the 2bF8 cassette 13 ( Figure 1A ). 2bF9 lentivirus (2bF9 LV) was packaged using a similar approach to that previously described for 2bF8 LV.
13
Animal procedures
Animal studies were approved by the Animal Care and Use Committee of the Medical College of Wisconsin. Transgenic mice were generated in the Transgenic Core Facility of the Blood Research Institute and Medical College of Wisconsin. All mice used in this study were on the C57BL/6 background. Isoflurane or 2.5% avertin was used for anesthesia.
Lentivirus-mediated transgenesis. 2bF9 transgenic mice were produced by lentivirusmediated transgenesis as reported. 19 Briefly, fertilized eggs were collected from the oviducts of wild type C57BL/6 mice. Approximately 10 to 100 pl of concentrated 2bF9
LV was injected into the perivitelline space of single-cell mouse embryos. After 24 
Integration site analysis
The 2bF9 transgene integration site was determined by inverse PCR. Details are provided in the supplemental data.
FIX assays
FIX antigen (FIX:Ag) assay. Blood samples were collected from mice and plasma or platelet isolation was performed as previously described. 15 A 96-well plate was coated with 1U/ml rhFIX. 100 μl diluted mouse plasma (1:100 in Tris-BSA) were added in duplicate wells and incubated at room temperature for 2 hours. were determined by modified Bethesda assay. 21 Sequential dilutions of mouse plasma were incubated with an equal volume of normal human plasma at 37ºC for 2 hours and residual FIX:C was subsequently measured using the chromogenic assay. One Bethesda unit (BU) is the amount of antibody that will inactivate 50% of normal human FIX:C.
Immuno-staining and western blot analysis of FIX
The localization of FIX transgene protein in 2bF9 mice was determined by immunofluorescent confocal microscopy, immunogold-labeled electron microscopy (EM), and immunohistochemical (IHC) staining. The physical properties of FIX were analyzed by western blot. Details are provided in the supplemental data.
Phenotypic correction
Tail clip survival tests were performed to assess phenotypic correction as previously described. 15 Eight-to twenty-week-old mice were selected for the test. For BMT recipients, the test was performed 8 weeks after BMT. For splenocyte-recipient mice, the test was performed 5 to 6 weeks after transplantation. For platelet or rhFIX infusion studies, infusions were performed by retro-orbital injections. Tail clipping was carried out 10 minutes, 24 hours, and 48 hours after platelet infusion or 5 minutes after rhFIX infusion. Whole blood clotting time (CT) was determined by rotational thromboelastometry (ROTEM) analysis. Details are provided in the supplemental data. The functional activity of platelet FIX was examined by both APTT assay and chromogenic assay ( Figure 2C ). We found that the chromogenic assay gave higher sensitivity and less variable results. Comparing FIX:C to FIX:Ag, platelet FIX had greater than 75% activity relative to antigen for both 2bF9-L and 2bF9-H mice. This suggests that most of the FIX can undergo γ -carboxylation in mouse platelets. To evaluate the properties of platelet FIX protein, mouse platelet lysates and releasates were analyzed by western blot for FIX. The results show that the apparent molecular weight of platelet FIX is slightly larger than normal human plasma FIX ( Figure 2D ), which agrees
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For personal use only. on October 24, 2017. by guest www.bloodjournal.org From with a previous in vitro study done in a human haematopoietic cell line by others, 22 suggesting the existence of a different pattern of glycosylation in megakaryocytes as compared to the normal FIX synthesis in hepatocytes.
FIX:Ag was also detectable in the plasma of 2bF9 transgenic mice. The average levels were 1.0 ± 0.3 mU/ml and 24.3 ± 7.3 mU/ml in 2bF9-L and 2bF9-H mice, respectively ( Figure 2E ). The detection limit of this assay is 0.08 mU/ml. To evaluate the distribution of FIX between plasma and platelets, we normalized FIX:Ag levels to total whole blood FIX content and compared platelet-lysate FIX:Ag to total FIX:Ag. About 90% of whole blood FIX was stored in platelets of both 2bF9-L and 2bF9-H mice ( Figure 2F ).
The localization of FIX in 2bF9 transgenic platelets
To address the localization of FIX protein in platelets, immunofluorescent confocal microscopy was performed to visualize FIX in transgenic platelets. Figure 3R ) or isotype controls ( Figure 3S ).
BMT from 2bF9 mice to FIX null mice
To determine whether the clinical efficacy of 2bF9 can be transferred by hematopoietic BMT-L and 2bF9-L mice ( Figure 2E ). The level of plasma FIX:Ag in BMT-H mice (10.8 ± 2.7 mU/ml) was significantly lower than in 2bF9-H donors (P < .01, Figure 2E ).
Consequently, the proportion of total FIX stored in platelets was higher in BMT-H mice than in 2bF9-H mice (95% vs. 90%, P < .01, Figure 2F ). ELISA, and western blot. The transgene mRNA was detected by qRT-PCR with the highest level in liver, which was only 0.0017-fold of that in 2bF9 transgenic platelets, followed by lung and kidney, with only a trace amount in the heart (Supplemental figure   1 ). No FIX protein was detected by IHC in any of these tissues (Supplemental figure 2).
FIX was also not detected by ELISA or western blot in tissue lysates (data not shown).
The fact that FIX antibody was undetectable in both BMT-L and BMT-H mice suggests To further investigate the function of platelet-derived FIX, clotting time (CT) was determined by ROTEM analysis. In contrast to FIX null mice, the mean CT was shortened from 2357 seconds to 1109 seconds in 2bF9-H mice (P < .01). There were no significant differences between WT and 2bF9-H in wild-type background (2bF9-H/WT) in which normal murine FIX is expressed in addition to platelet FIX (P = .46) ( Figure 5C ).
To examine whether ectopic platelet FIX expression would interfere with normal platelet function or potentially causes prothrombotic complications, we kept four 2bF9-H mice in a wild-type background and monitored them for more than 1.5 years. All of the mice were healthy until the end of the study with no overt evidence of tumors or health To further confirm the benefit of platelet FIX in phenotypic correction, platelets from 2bF9-H mice were transfused into FIX null mice to attain a 30% proportion of total recipient platelets, and groups of mice were then challenged by tail clipping 10 min, 24
hours, and 48 hours after the infusion. All three groups survived tail clipping. No FIX null control mice that received FIX null platelets survived the same challenge ( Figure 5D ).
These results demonstrate that platelet FIX can be transferred not only by BMT but also by platelet infusion alone.
To assess if platelet-derived FIX is still functional in the presence of FIX inhibitory antibodies, we repeated the platelet infusion study with rhFIX immunized FIX null mice, which had developed FIX inhibitory antibodies. None of these mice survived tail clipping after platelet infusion ( Figure 5D ). We also transplanted splenocytes from immunized FIX null mice into sublethally irradiated 2bF9-H mice. Two weeks after transplantation, all recipients developed FIX inhibitory antibodies with titers between 1 BU/ml and 124 BU/ml. At 5 to 6 weeks, the inhibitor titers had decreased in all of the recipients, and in 3 mice had dropped to less than 1 BU/ml. At this time, tail clip survival tests were performed. The 3 mice which had inhibitor titers less than 1 BU/ml survived tail clipping, while only 2 of 10 mice with inhibitor titers higher than 1 BU/ml survived the test ( Figure   5E ). Platelet counts in both of these groups were normal (data not shown). The Recent studies have shown that not all general secretory proteins are packaged within secretary granules when synthesized by megakaryocytes. Fukami and co-workers showed that factor VII (FVII), which is also a vitamin K-dependent protein and shares a high degree of structural and sequence homology with FIX, is found in the cytoplasm rather than in granular storage when targeted to the platelet lineage. 31 Therefore, the plasma FIX in 2bF9 genetic modified mice may be beneficial in immune tolerance induction. This will be further investigated by our group. Platelet infusion studies showed that the clinical efficacy can be maintained at least for 48 hours even when only a fraction (30%) of the circulating platelets contain FIX. This level should be achievable because our previous study has demonstrated that our lentivirusmediated platelet-specific gene transfer system can efficiently introduce transgene expression in greater than 50% of megakaryocytes. 50 Our FVIII studies have demonstrated that lentivirus-mediated BM transduction and syngeneic BMT can efficiently introduce transgene FVIII expression in the platelet lineage, resulting in therapeutic levels of platelet-FVIII in hemophilia A mice. A similar approach will be applied to 2bF9 gene transfer to explore the feasibility of platelet-derived FIX gene therapy of hemophilia B.
In conclusion, our study demonstrates that storage of FIX in platelet α -granules can be achieved by ectopically expressing FIX in the platelet lineage. Activation of platelets releases FIX, which is effective in correcting the phenotype of hemophilia B even at a 
